Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer
Non-randomised trial
OA: closed
CC0
AI-generated summary
This paper investigated the combination of tamoxifen, aminoglutethimide, danazol, and medroxyprogesterone acetate in patients with advanced breast cancer.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Seventy-four post-menopausal women with metastatic breast cancer were treated with a combination hormonal regimen consisting of tamoxifen, aminoglutethimide danazol and medroxyprogesterone acetate (POND). 72% of the patients had received no previous treatment. The overall response rate (complete and partial remission) was 43.5% with a median response duration of 19 months and a median survival of 27 months. The most common sites of response were in regional nodes and local chest wall disease. The major side-effects were those expected from the individual agents: nausea, lethargy, rash and oedema.
My notes (saved in your browser only)
MeSH descriptors
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (4)
- Danazol 1982
- Danazol treatment of advanced breast cancer 1981
- Clinical trial of multiple endocrine therapy for metastatic and locally advanced breast cancer with tamoxifen-aminoglutethimide-danazol compared to tamoxifen used alone 1982
- Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially 1984
References (25)
- Clinical trial of multiple endocrine therapy for metastatic and locally advanced breast cancer with tamoxifen-aminoglutethimide-danazol compared to tamoxifen used alone via openalex
- Danazol via openalex
- Danazol treatment of advanced breast cancer via openalex
- Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially via openalex
- W2341178074 via openalex
- W2410234626 via openalex
- W2410597202 via openalex
- doi:10.7326/0003-4819-98-2-139 via openalex
- doi:10.1200/jco.1986.4.6.958 via openalex
- doi:10.2165/00003495-197816010-00001 via openalex
- W2466097117 via openalex
- W2467643320 via openalex
- W2528647102 via openalex
- W6637884266 via openalex
- W6643992471 via openalex
- W6676685655 via openalex
- W6683618316 via openalex
- doi:10.1016/s0167-8140(87)80233-5 via openalex
- doi:10.2165/00003495-198835060-00005 via openalex
- doi:10.1038/bjc.1977.42 via openalex
- doi:10.1016/0277-5379(83)90390-5 via openalex
- doi:10.1007/bf01886735 via openalex
- doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 via openalex
- W2113115816 via openalex
- W2161718563 via openalex
SciLite annotations
chemicals 10
tamoxifen
aminoglutethimide
danazol
medroxyprogesterone
acetate
tamoxifen
aminoglutethimide
danazol
medroxyprogesterone
acetate
Source provenance
- openalex
- last seen: 2026-05-11T05:49:40.447239+00:00
- pubmed
- last seen: 2026-10-08T21:08:47.456808+00:00
- scilite
- last seen: 2026-05-18T04:57:49.680383+00:00
- unpaywall
- last seen: 2026-10-14T06:23:58.021457+00:00
License: CC0
· commercial use OK